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has resulted in a worldwide pandemic. SARS-CoV-2 is highly contagious and its
severity highly variable. The fatality rate is unpredictable but is amplified by several
factors including advancing age, atherosclerotic cardiovascular disease, diabetes
mellitus, hypertension and obesity. A large proportion of patients with these conditions
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are treated with lipid lowering medication and questions regarding the safety of
continuing lipid-lowering medication in patients infected with COVID-19 have arisen.
Some have suggested they may exacerbate their condition. It is important to consider
known interactions with lipid-lowering agents and with specific therapies for COVID-19.
This statement aims to collate current evidence surrounding the safety of lipid-lowering
medications in patients, who have COVID-19. We offer a consensus view based on
current knowledge. In a rapidly emerging field new therapies will need to be assessed
in the same way.&lt;/p&gt; &lt;p&gt;&lt;em&gt;Methods:&lt;/em&gt; Pubmed, Google
scholar and Web of Science were searched extensively for articles using search terms:
SARS-CoV-2, COVID-19, coronavirus, Lipids, Statin, Fibrates, Ezetimibe, PCSK9
monoclonal antibodies, nicotinic acid, bile acid sequestrate, nutraceuticals, red yeast
rice, Omega-3-Fatty acids, Lomitapide, hypercholesterolaemia, dyslipidaemia and
Volanesorsen.&lt;/p&gt; &lt;p&gt;&lt;em&gt;Results
&amp;amp;Conclusions:&lt;/em&gt;&lt;/p&gt; &lt;p&gt;There is no evidence currently
that lipid lowering therapy is unsafe in patients with COVID-19 infection. Lipid-lowering
therapy should not be interrupted because of the pandemic or in patients at increased
risk of COVID-19 infection. In patients with confirmed COVID-19, care should be taken
to avoid drug interactions, between lipid-lowering medications and drugs that may be
used to treat COVID-19, especially in patients with abnormalities in liver function
tests.&amp;nbsp;&lt;/p&gt; &lt;/div&gt; &lt;/div&gt;&lt;/div&gt; &lt;/p&gt;
&lt;/div&gt;&lt;/div&gt; &lt;/p&gt; &lt;/div&gt;&lt;/div&gt; &lt;/p&gt; &lt;/div&gt;&lt;/div&gt;
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Highlights  
 
- Patients with known atherosclerotic cardiovascular disease and related 
comorbidities are at increased risk of severe illness and mortality if infected with 
COVID-19. 
 
- There is no convincing evidence to suggest harm from lipid lowering therapy or on-
treatment low LDL cholesterol if patients develop acute illnesses or SARS-CoV-2. In 
fact, available evidence suggests that statin therapy is associated with benefits. 
 
- Patients treated for hyperlipidaemia should not interrupt their treatment because of 
COVID-19 pandemic.  
 
- Continue lipid lowering therapy in patients with confirmed diagnosis of COVID-19 
unless possible risks outweigh benefits.  
 
- In patient treated for COVID-19 with pharmacologic agents, drug interactions with 
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Continue unless:
• ALT or AST rises progressively or ALT 
and/or AST is greater than 3 times the 
upper limit of normal (1, B-R). 
• Clinical or biochemical evidence of 
myopathy or myositis (1, B-R). 
• Dose reduction or alternative statin if 
significant drug-drug interaction 
identified  (1, C-LD).
Statins
Continue unless:
• A significant drug-drug interaction 
identified  (1, C-LD).
• ALT or AST rises progressively, or ALT 
and/or AST is greater than 3 times the 
upper limit of normal (1, B-R). 
• Clinical evidence and/or biochemical 
evidence of myopathy or myositis (1, B-R).
• Acute kidney injury (1, B-NR).
Fibrates
Continue unless:
• A significant drug-drug interaction 
identified (1, C-LD).
• ALT and/or AST rises above 3 times the 
upper limit of normal (1, B-R). 
Ezetimibe
Continue unless:
• Critically ill patients (1, E-EO). 
• Individualised risk vs. benefit assessment 
to restart treatment after patient’s 
condition has improved (1, B-NR). 
PCSK9 Inhibitors
Bile Acid Sequestrants:
Discontinue temporarily in patients 
diagnosed with COVID-19 (1, C-LD).
Niacin:
Discontinue temporarily in patients 
diagnosed with COVID-19.
Other Medications
• Patients should continue with their advised diet and lifestyle measures and should not interrupt their pharmacologic treatment 
because of the COVID-19 pandemic (I, A). 
• Oral lipid lowering medications can be suspended temporarily in patients with confirmed COVID who are too unwell for oral 
administration (I, E-EO). 
• In rare and inherited disorders such as Homozygous Familial Hypercholesterolemia (HoFH),  Heterozygous Familial 
Hypercholesterolemia (HeFH), Familial Chylomicronaemia Syndrome (FCS) it would be good practice to consult with a lipid specialist to 
assess specific risks and therapeutic challenges (Ia, E-EO). 
• Continue lipid lowering therapy in patients with confirmed diagnosis of COVID-19 and abnormal liver functions tests (LFTs) unless 
alanine transaminase (ALT) or aspartate transaminase (AST) rises progressively (1, B-R). 
• Stop lipid lowering therapy and monitor if ALT or AST is greater than 3 times the upper limit of normal (I, B-R). 
• Creatine kinase measurements should be considered when clinically indicated and in patients who are critically ill. Discontinue statin 
therapy temporarily if creatine kinase rises 10-fold to levels about 2,000 IU/L or more in asymptomatic patients or at a lower levels of 
5-fold upper limit of normal in symptomatic patients (I, B-R). 




• Critically ill (1, C-EO).
• Individualised risk vs. benefit 
assessment to restart treatment when 
patient’s condition has improved (1, B-
NR).
Omega-3-Fatty Acids
Lipoprotein apheresis is safe and should 
be continued if logistically possible (1a, C-
LD).
For other medications including 
Lomitapide and Volanesorsen please refer 
to recommendations 10 and 11.
HoFH and FCS
Graphical Abstract
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Abstract 
Background & aims: The emergence of the novel severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) which causes Coronavirus Disease 2019 (COVID-19) has resulted in a worldwide 
pandemic. SARS-CoV-2 is highly contagious and its severity highly variable. The fatality rate is 
unpredictable but is amplified by several factors including advancing age, atherosclerotic 
cardiovascular disease, diabetes mellitus, hypertension and obesity. A large proportion of patients 
with these conditions are treated with lipid lowering medication and questions regarding the safety 
of continuing lipid-lowering medication in patients infected with COVID-19 have arisen. Some have 
suggested they may exacerbate their condition. It is important to consider known interactions with 
lipid-lowering agents and with specific therapies for COVID-19. This statement aims to collate 
current evidence surrounding the safety of lipid-lowering medications in patients, who have COVID-
19. We offer a consensus view based on current knowledge and we rated the strength and level of 
evidence for these recommendations.   
Methods: Pubmed, Google scholar and Web of Science were searched extensively for articles using 
search terms: SARS-CoV-2, COVID-19, coronavirus, Lipids, Statin, Fibrates, Ezetimibe, PCSK9 
monoclonal antibodies, nicotinic acid, bile acid sequestrate, nutraceuticals, red yeast rice, Omega-3-
Fatty acids, Lomitapide, hypercholesterolaemia, dyslipidaemia and Volanesorsen.  
Results & Conclusions:  There is no evidence currently that lipid lowering therapy is unsafe in 
patients with COVID-19 infection. Lipid-lowering therapy should not be interrupted because of the 
pandemic or in patients at increased risk of COVID-19 infection. In patients with confirmed COVID-
19, care should be taken to avoid drug interactions, between lipid-lowering medications and drugs 







































































The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes Coronavirus 
Disease 2019 (COVID-19), infects cells of the respiratory tract via receptor-mediated endocytosis 
after interaction with the angiotensin converting enzyme receptor 2 (ACE2) protein [1]. Lipid 
lowering therapy is generally considered safe; however, there are theoretical concerns regarding 
their contribution to infectivity and safety in patients with COVID-19 pneumonia or acute respiratory 
distress syndrome (ARDS).  Baseline characteristics of patients who required critical care unit 
admission due to COVID-19 from Lombardy, Italy, revealed that there was an 18% prevalence of 
hypercholesterolaemia as a co-morbid condition [2]. In a case series of patients suffering from 
COVID-19, 35.3% of patients were found to have underlying atherosclerotic cardiovascular disease 
and this was associated with a 50% fatality rate [3]. Similarly, data from New York showed that 26% 
of patients hospitalised because of COVID-19 were reported to have hyperlipidaemia as a co-morbid 
condition and 10% were known to have coronary artery disease [4]. In non-hospitalised COVID-19 
patients, however, the prevalence of hyperlipidaemia and coronary artery disease (CAD) was 11% 
and 2%, respectively. Of the hospitalised patients, there was a similar prevalence of hyperlipidaemia 
(27% vs. 24%) and CAD (12% vs. 9%) in those admitted to critical care vs. discharged from hospital 
(and thereby not requiring any ventilatory or other supportive therapy). In a multivariate regression 
analysis assessing risk factors for hospitalisation, including age, cancer, chronic kidney disease, CAD, 
hypertension, hyperlipidaemia, heart failure, obesity, pulmonary disease, race, male sex and tobacco 
use, the odds ratio (OR) for hyperlipidaemia (OR 0.67; p=0.003) suggested a relative reduction in the 
individual proportional risk for hospital admission [4]. However, the authors did not mention how 
many of the hyperlipidaemic patients were on statins or other lipid lowering therapies. Hu et al. 
recently reported lower serum cholesterol levels amongst COVID-19 patients [5], leading some to 
suggest temporary cessation of lipid lowering therapy [6]. However, lipid parameters often fall in 
cytokine-mediated inflammation as a consequence of the acute phase response rather than having a 
causative or pathological contribution towards infection [7-9]. It is reasonable to assume that 
patients with previous history of myocardial injury are at higher risk for further events, thereby 







































































The aim of this consensus statement is to provide recommendations on the continuation, alteration 
or cessation of lipid-lowering therapies in patients with COVID-19 infection based on the currently 
available evidence, especially when considering concurrent novel therapeutic options for COVID-19 
used in clinical trials. We aim to provide, in the absence of a high-quality clinical trial evidence, a 
consensus statement by HEART UK (Hyperlipidaemia Education and Atherosclerosis Research Trust 
in United Kingdom) largely based on experts’ opinion to provide a guide for managing 
hyperlipidaemia during the SARS-CoV-2 pandemic. Considering the differences between health care 
systems in different countries, this consensus statement is not intended to be didactic but rather it 
aims to provide advice to clinicians on the safe use of lipid lowering therapies during this pandemic.   
 
Method and search strategy 
 
Pubmed, Google scholar and Web of Science were searched extensively for articles using search 
terms: SARS-CoV-2, COVID-19, Lipids, Statin, Fibrates, Ezetimibe, PCSK9 monoclonal antibody, 
Omega-3-Fatty acids, Lomitapide, hypercholesterolaemia, dyslipidaemia, lomitapide and 
Volanesorsen. A core team assessed the data and presented an outline to the group. After initial 
discussions, the core group produced the first draft followed by extensive discussion and editing via 
teleconferences, video links and electronic mail until a consensus was reached. We did not include 
lipid lowering drugs in development because of marked paucity of data. Patients who are taking 
such medications, as part of a clinical trial, should be discussed with the respective clinical trials 
team. We rated the strength and level of evidence for these recommendations based on the 




Patients with no symptoms or diagnosis of COVID-19 should continue their lipid-lowering 
medications, as well as other cardio-protective therapies, as usually prescribed. Our general advice is 
consistent with previous assessments and recommendations [11-13]. 
There is no need to withhold lipid-lowering medications during the COVID-19 pandemic. This is 
especially important in patients who are at high risk of cardiovascular disease, in whom stopping 
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Recommendation 1  
- Patients treated for hyperlipidaemia should continue with their advised diet and lifestyle 
measures and should not interrupt their pharmacologic treatment because of the COVID-19 
pandemic (I, A).  
- Lipid lowering medications can be suspended temporarily in patients with confirmed COVID-
19, who are too unwell to receive medications orally (I, E-EO).  
- Creatine kinase measurements should be considered when clinically indicated and in 
patients who are critically ill. We recommend stopping statin therapy if creatine kinase rises 
10-fold to levels above 2,000 IU/L in asymptomatic patients or at a lower level of 5-fold 
upper limit of normal in symptomatic patients (I, B-R).  
- It is important to reassess and recommence oral lipid lowering medications in patients who 
recover before or soon after they leave hospital (I, B-NR).  
- In rare and inherited disorders such as homozygous familial hypercholesterolemia (HoFH) 
(see below), heterozygous familial hypercholesterolemia (HeFH), familial chylomicronaemia 
syndrome (FCS). it would be good practice to consult with a lipid specialist to assess specific 
risks and therapeutic (see recommendations 10 and 11 below) challenges (Ia, E-EO).  
Abnormal liver functions tests in COVID-19 patients 
Abnormal liver function tests are increasingly recognised as a feature of COVID-19 infection with a 
prevalence as high as 37.2% at admission [14]. There is some evidence to suggest that men are 
affected more than women, and older age and higher initial viral load increase predisposition [15]. It 
is not clear if COVID-19 causes direct liver injury or if this is part of the wider systemic inflammatory 
response syndrome. Nonetheless, it is important to recognise hepatic injury in COVID-19 patients as 
the majority of lipid lowering therapies are metabolised in the liver.   
Recommendation 2:  
- Continue lipid lowering therapy in patients with confirmed diagnosis of COVID-19 and 
abnormal liver functions tests (LFTs) unless alanine Transaminase (ALT) or Aspartate 
Transaminase (AST) rises progressively (1, B-R).  
- Stop therapy and monitor if ALT or AST is greater than 3 times the upper limit of normal (I, 
B-R).  
- Reassess and consider recommencing oral lipid lowering medications in patients who 
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Statins are 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitors. They have shown great efficacy in 
treating a variety of lipid disorders whilst also providing mortality benefits against cardiovascular 
disease [16, 17]. Studies on the pharmacodynamic properties of statins have shown they have 
pleiotropic properties with effects that may modulate inflammation [18], sepsis [19], immunity [20], 
and vasomotor tone [21]. Of relevance in the current COVID-19 pandemic is the effect of statins on 
ACE2 receptor expression. Pharmacologic blockade of the renin-angiotensin-aldosterone system has 
generally been shown to upregulate ACE2 expression in a variety of tissues [22]. This has led some to 
question the safety of such therapies in patients who test positive for COVID-19 with advocates for 
both sides [23-25]. Shin et al. showed that a combination of fluvastatin and insulin upregulated ACE2 
expression in murine cardiac muscle cells [26]. A study by Tikoo et al. found that atorvastatin can 
upregulate ACE2 expression in cardiac tissue when animals were fed high cholesterol diets [27]. 
Similar findings were reported by Aguilar et al. in a murine model [28] and Li et al. found 
rosuvastatin upregulated ACE2 expression in murine vascular smooth muscle cells [29]. Conclusions 
from these data highlight the beneficial role of statins in mediating attenuation of cardiovascular 
risk, however, amidst the current COVID-19 pandemic, there is concern about pharmacologic 
upregulation of the ACE2 receptor, for example with ACE-inhibitor treatment. A joint statement by 
the Council on Hypertension and the European Society of Cardiology has advised physicians to 
continue treatment with their current regimen, even though these drugs can raise ACE2 levels [30]. 
The safety of the ACE-inhibitor therapy has been subsequently been evaluated in observational 
studies, which did not show any adverse outcome [31, 32]. Given the current lack of sufficient 
convincing evidence to confirm adverse outcomes and benefits of these drugs, the American Society 
for Preventive Cardiology advised that patients should continue their cardioprotective drugs [13]. 
Emerging evidence suggests that ACE2 blockade may indeed be beneficial [25, 33]. Importantly, no 
human or animal data exist on the relationship between pulmonary ACE2 receptors and statin 
therapy. Furthermore, statins could be efficient SARS-CoV-2 main protease inhibitors and, in theory, 
may alleviate COVID-19 symptoms [34]. 
One study has demonstrated endothelial cell involvement across vascular beds of different organs in 
a series of patients with COVID-19, suggesting that SARS-CoV-2 infection facilitates the induction of 
inflammation of the endothelium in several organs as a direct consequence of viral involvement and 
of the host inflammatory response [35]. In addition, induction of apoptosis and pyroptosis may have 
an important role in endothelial cell injury in patients with COVID-19. Inflammation of the 
endothelium could explain the systemic impaired microcirculatory function in different vascular beds 
and their clinical sequelae in patients with COVID-19. This hypothesis provides a rationale for 
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inflammatory anti-cytokine drugs, ACE inhibitors, and statins. Indeed, a recent study reported that 
use of ACE inhibitors or statins was associated with better survival among patients with Covid-19 
[10]. 
Bilateral diffuse alveolar damage with cellular fibromyxoid exudates has been found in COVID-19 
infection [36]. These changes may cause acute respiratory distress syndrome (ARDS), with a 
reported prevalence in COVID-19 of 8.2% [37]. A systematic review from 2019 concluded that in 
ARDS patients, statins make little or no difference to early mortality or duration of ventilation, 
suggesting their safety in this setting [38]. A UK-based observational study of 2067 patients 
suggested that statins may impart a mortality benefit in patients with community acquired 
pneumonia [39]. In contrast, however, a multicentre cohort study from the United States found no 
evidence of protection conferred by statins on clinical outcomes in a similar cohort [40]. A meta-
analysis found that although statin treatment was associated with decreased mortality after 
pneumonia, there was attenuation of this effect in certain subgroups and it was indicated that no 
robust conclusions could be drawn without a dedicated randomised clinical trial [41]. Data on 
protectiveness of statins in viral pneumonias are also inconsistent with studies reporting benefit [42-
44] or no benefit [45]. Pertinently, in another coronavirus related disease, Middle Eastern 
Respiratory Syndrome (MERS), statins were postulated to protect against mortality [46].  There are 
also some studies which have shown a beneficial role of statins in sepsis [47], and this is not 
unfounded given their anti-oxidant, anti-inflammatory and immunomodulatory properties [48, 49]. 
Longer-term data are required, however, before such claims can be substantiated. Notwithstanding 
the somewhat conflicting data on the benefits of statin use in pneumonia, no studies so far have 
demonstrated a negative effect on outcome.  Patients with tuberculosis, receiving statin treatment 
responded more rapidly to anti-tuberculous drugs and had lower rates of reactivation [50]. This 
effect is likely to be due to the decrease in circulating low-density lipoprotein cholesterol (LDL-C) 
rather than to a direct effect on the bacterium itself or the macrophage foam cellsm which are its 
host in the tuberculoma, because very little statin survives its first pass through the liver to reach the 
lungs [51]. 
Red yeast rice (RYR), a nutraceutical that inhibits HMG-CoA reductase and reduces LDL-C [52], is 
used by some patients who are intolerant to statins [53]. It is enzymatically hydrolysed in the small 
intestine and liver by cytochrome P450. There is little if any data on RYR interactions with drugs 
potentially used for COVID-19. The pharmaceutical properties of different RYR preparations varies. If 
the patient is on RYR and no evidence of COVID-19, there is no need to stop treatment, however, it 
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Lipid metabolism changes in patients with acute illness and sepsis; high density lipoprotein 
cholesterol (HDL-C) tends to lose its anti-inflammatory effect and LDL-C tends to be more 
susceptible to atherosclerotic modifications [51]. Furthermore, atherosclerotic plaques may become 
more vulnerable to rupture predisposing to an acute cardiovascular event, so it is importance to 
continue with lipid modifying agents except in cases where risks outweigh benefits.  
Recommendation 3:  
Statin therapy should be continued in patients with confirmed diagnosis of COVID-19 (1, C-LD) but 
should be stopped, or dose reduced if: 
- ALT or AST rises progressively. Stop statin therapy and monitor if ALT or AST is greater than 3 
times the upper limit of normal (1, B-R).  
- There is a significant drug-drug interaction identified (table 2). Consider reducing the dose or 
change to another statin (table 2) (1, C-LD). 
- We recommend stopping statin therapy if creatine kinase rises 10-fold to levels about 2,000 
IU/L or more in asymptomatic patients or at a lower level of 5-fold upper limit of normal in 
symptomatic patients (1, B-R).  
- If there is evidence of myositis, renal function should be monitored (1, B-NR). 
- If treatment is suspended, a further individualised risk vs. benefit assessment should be 
conducted to restart treatment soon after the patient’s condition has stabilised (1, B-NR). 
Fibrates 
Fibrates are peroxisome proliferator-activated receptor alpha (PPAR-α) agonists and are used 
primarily in the treatment of hypertriglyceridemia [54]. Elevated triglyceride levels are associated 
with inflammation [55], and used as part of the H-Score, which determines the presence of 
secondary haemophagocytic lymphohistiocytosis, an under-recognised hypercytokinaemia 
syndrome thought to occur in COVID-19 infection [56]. Similar to statins, fibrates are also known to 
have anti-inflammatory properties and have been suggested as a potential anti-viral agent [44]. 
Indeed, it has been shown that gemfibrozil confers survival benefits in mice infected with severe 
H2N2 influenza [57], and prolonged survival has been demonstrated in mice when combined with 
oseltamivir [58]. Despite these animal data, there are no studies on the effects of fibrates on 
respiratory viral infections in humans. A case report described an association between eosinophilic 
pneumonia and clofibrate [59]. Fibrates are generally well tolerated with the major concerns being 
muscle-related side effects [60]. Although the absolute risk is very small, there is an aggregated risk 
of myopathy and myositis when used in combination with statins, in particular gemfibrozil (which is 
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tolerability, evidence suggests that they may cause a mildly reversible elevated creatinine [63], a 
slight increase propensity towards cholelithiasis [64] and an augmented response of anti-coagulants 
such as warfarin [65]. 
Fibrates are primarily used for hypertriglyceridaemia [66]. Fibrates are metabolised by cytochrome 
P450 isoenzyme 2C9 (CYP2C9) whilst may also mildly inhibit this enzyme [67], they are renally 
excreted, and therefore doses should be reduced in patients with an eGFR <60 ml/min/1.73m2 and 
stopped if the eGFR drops below 15 ml/min/1.73m2 [62]. No drug interactions have been reported 
between the commonly used fibrates and the proposed drugs on trial for treating COVID-19 (table 
3).   
Recommendation 4:  
Fibrate therapy should be continued in patients with and without a confirmed diagnosis of COVID-19 
(1, C-LD) unless:  
- There is a significant drug-drug interaction identified (table 3) (1, C-LD). 
- ALT or AST rises progressively, when fibrate therapy should be stopped if ALT or AST 
is greater than 3 times the upper limit of normal (1, B-R).  
- There is clinical evidence and/or biochemical evidence of myopathy or if creatine 
kinase is greater than five times upper limit of normal (1, B-R). 
- Acute kidney injury with deteriorating estimated glomerular filtration rate (eGFR) (1, 
B-NR). 
- Assess drug interactions if oral anticoagulants are initiated (1, C-LD). 
- If treatment is suspended, further assessment should be conducted to restart 
treatment soon after the patient’s condition has stabilised (1, B-NR). 
Ezetimibe 
Ezetimibe selectively blocks the Niemann-Pick C1-like Protein (NPC1L1) in the jejunal brush border, 
resulting in the inhibition of dietary cholesterol absorption [68] and was shown to reduce LDL-C and 
ASCVD risk [68-70]. Ezetimibe is considered a safe therapeutic option with few side effects and no 
known drug interactions with the proposed medications being trialled for COVID-19. No trials 
reporting long-term outcome of ezetimibe use in viral or bacterial pneumonia have been conducted.  
Recommendation 5:  
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- There is a significant drug-drug interaction identified (table 4) (1, C-LD). 
- ALT and/or AST rises above 3 times the upper limit of normal (1, B-R).  
- If treatment is suspended, further assessment should be conducted to restart treatment 
soon after the patient’s condition has stabilised (1, B-NR). 
PCSK9 monoclonal antibodies 
Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies are novel drugs that 
reduce LDL-C to previously unprecedented levels [71].  They reduce cardiovascular events [72-74], 
are well tolerated  and safe [75]. However, given their novelty, longer term safety data is still 
required. The PCSK9 protein is often upregulated during sepsis and inflammation and is postulated 
to have a detrimental effect on host response and survival [76, 77]. This has led some to argue for a 
possible role of PCSK9 monoclonal antibodies in treating the dysregulated immune response during 
infection [78]. However, a review by Ruscica et al. found no significant reductions in high-sensitivity 
C-reactive protein in patients receiving PCSK9 monoclonal antibodies from clinical trial data [79]. 
Whilst there is some evidence that PCKS9 inhibitors may modulate the inflammatory response in 
atherosclerosis, their utility in dampening inflammation and benefit during sepsis is a matter of 
debate. Although an increased frequency of nasopharyngeal symptoms and flu-like syndrome have 
been reported amongst recipients in PCSK9 monoclonal antibody studies [75], it is unclear whether 
this translates into an increased susceptibility to respiratory viruses such as COVID-19. Flu-like 
symptoms are a class effect of monoclonal antibodies and therefore such results are unsurprising 
[80]. 
Whilst very limited drug-drug interaction data is available, pharmacokinetic data indicates that likely 
they are safe, as drug elimination occurs via saturable binding to PCSK9, with no clinically significant 
differences in patients with hepatic or renal impairment or with other concomitant drug use [81].  
Vuorio et al. recommended the continuation of these drugs in patients who have familial 
hypercholesterolaemia (FH) and have contracted COVID-19 [12].  The rationale for this was that 
patients with FH are at higher risk of atherosclerotic cardiovascular events.  
Recommendation 6:  
PCSK9 monoclonal antibodies should be continued in all patients with a confirmed diagnosis of 
COVID-19 (table 4).  
- In critically ill patients, treatment can be paused until recovery and discharge from the 


































































HEART UK Consensus statement: Lipid lowering therapy in COVID 19 
 11 
- If treatment is suspended or delayed, a further individualised risk vs. benefit assessment 
should be conducted to restart treatment soon after patient’s condition has stabilised (1, B-
NR).  
Omega-3 fatty acids  
Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in sufficient amounts reduce 
triglyceride levels [82-84], and have been associated with favourable effects on various markers of 
cardiovascular risk such as reduced blood pressure [85, 86], and decreased platelet aggregation [87]. 
Their anti-inflammatory properties [88], and potential role in atherosclerotic plaque stability, have 
also been described [89, 90].  Despite this, there remains some controversy surrounding the 
evidence for cardiovascular outcome benefits [91-94]. Most recently, the REDUCE-IT (Reduction of 
Cardiovascular Events with EPA-Intervention Trial) study demonstrated a significant decrease in  
residual risk of cardiovascular events in patients with atherosclerotic cardiovascular disease and 
elevated triglyceride levels [95]. There is no available evidence on the use of omega-3 fatty acids in 
acute infection or illness although there are no clear mechanistic reasons that raise safety concerns.  
There are no significant drug interactions between possible trial therapies for COVID19 and omega-3 
fatty acids (table 4). It has been suggested that they may prolong bleeding time [96], however, 
clinical trials have not shown adverse outcomes in relation to this [97, 98]. 
Recommendation 7:  
Omega-3 fatty acids can be continued in patients with confirmed diagnosis of COVID-19 unless: 
- The patient is critically ill (1, C-EO). 
- If treatment is suspended, a further individualised risk vs. benefit assessment should be 
conducted to restart treatment when patient’s condition has improved (1, B-NR). 
 
Bile acid sequestrants  
The bile acid sequestrants such as cholestyramine, colesevalam and colestipol are highly positive 
charged molecules, which interact with negatively charged bile acids preventing their absorption in 
the intestines [99]. They are not absorbed themselves and therefore do not interact 
pharmacologically with other agents; however, they may inhibit the absorption of a number of orally 
administered drugs [100].  
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In the absence of cardiovascular outcome data and given the potential for interfering with drug 
absorption, it would be reasonable that bile acid sequestrants are discontinued in patients 
diagnosed with COVID-19 (1, C-LD). 
Nicotinic acid (niacin) 
Niacin positively impacts apo-B containing lipoproteins whilst favourably increasing apo A1 [101, 
102]. This translates into reductions in LDL-C and triglycerides whilst concomitantly raising HDL-C 
[103, 104]. Despite the lack of cardiovascular efficacy when added to background statin therapy 
[105], its ubiquitous use continues worldwide [101, 106]. Niacin often causes facial flushing as a side 
effect, which sometimes limits its use in general practice [107]. Niacin undergoes conjugation with 
glycine in the liver producing its major metabolite, nicotinuric acid, which is excreted in urine [103]. 
Niacin has been shown to attenuate endotoxemic lung inflammation in animal models [108], 
however, hard data in human viral infections is lacking. No reports questioning its safety profile have 
been reported during the previous SARS and MERS outbreaks.  
Recommendation 9: Niacin therapy can be continued in patients without COVID-19, however, in the 
absence of consistent clinical trials evidence to support cardiovascular events prevention, we 
recommend discontinuing niacin temporarily in patients diagnosed with COVID-19 (1, C-LD).  
Homozygous familial hypercholesterolaemia 
Homozygous familial hypercholesterolemia confers high cardiovascular risk from a very young age 
[109, 110]. Atherosclerotic plaque burden is high and there is particular concern about stopping lipid 
lowering therapies. Treatment is based on maximum tolerated oral lipid lowering agents, PCSK9 
inhibitors and lipoprotein apheresis [109-111].  In addition, lomitapide has been developed 
specifically for the condition [111]. 
Lomitapide inhibits microsomal triglyceride transfer protein (MTP) in hepatocytes and enterocytes, 
reducing apoB-containing lipoprotein particles secreted into the circulation [112]. It is currently used 
as adjunctive therapy for HoFH, achieving LDL-C reductions of 35.6% to 45.5% in Phase III and 
extension trials [113, 114]. This is consistent with real world clinical experience reported so far, with 
68% and 42% of patients achieving LDL-C <100 mg/dl (2.5 mmol/l) and <70 mg/dl (1.8 mmol/l), 
respectively [115]. Its mechanism of action also explains the adverse events of hepatic steatosis and 
elevated transaminases.  
Lomitapide is metabolised in the liver through CYP3A4 and lomitapide is also an inhibitor of CYP3A4 
[116]. Its excretion occurs through both renal and intestinal routes. There are therefore significant 
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Macrolide antibiotics, potent enzyme inhibitors, are common antimicrobial options in the treatment 
of pneumonia and therefore likely the most frequent drug interaction to be encountered in the 
management of COVID-19. Similarly, the concurrent use of protease inhibitors lopinavir and 
ritonavir, both predicted to markedly increase exposure to lomitapide through potent CYP3A4 
inhibition, is contraindicated.        
Due to the rarity of HoFH, there is currently no available data on the effect of lomitapide on 
outcomes in acute infection or illness. Monitoring is required with the use of lomitapide because of 
possible liver injury. This is dose related and, if interacting drugs are necessary, it should be 
discontinued.  
Recommendation 10:  
Patients with HoFH are at high risk of cardiovascular events and any proposed changes to therapy in 
these patients should be discussed with a lipid specialist familiar with the management of the 
condition. If a patient with HoFH is admitted into hospital, a discussion between the acute hospital 
team and lipid specialist should occur at the earliest opportunity. For specific treatment strategies 
we recommend: 
- For statins, evolocumab, ezetimibe, fibrates, omega-3 fatty, bile acids sequestrants please 
refer to the recommendations above. 
- Lipoprotein apheresis is safe and should be continued if logistically possible (1a, C-LD). 
- Lomitapide should be continued in patients with confirmed diagnosis of COVID-19 (1a, C-EO) 
unless: 
o There is a drug-drug interaction identified (table 4). Lomitapide can be temporarily 
discontinued in acutely ill patients and/or those who are started on anti-microbial 
medication with significant drug-drug interactions (table 4) (1, C-LD).  
o The patient develops significant gastrointestinal symptoms (1, C-LD). 
o The patient is critically ill and/or unable to take oral medications (1, C-EO). 
o Stop treatment if progressive rise in ALT and/or AST or if ALT any above 3 times the 
upper limit of normal (1, C-LD).  
o If treatment is withheld for any reason, further individualised risk vs. benefit 
assessment should be conducted to restart treatment when the patient has 
recovered (1, B, NR). 
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Familial chylomicronaemia syndrome (FCS) is characterised by very high triglyceride levels and 
increased risk of acute pancreatitis [117].  The cornerstone of current management is a low-fat 
intake. Volanesorsen is a newly licensed antisense oligonucleotide inhibitor of apolipoprotein CIII 
(Apo CIII) [118]. [119]. It is delivered on a 2-weekly basis via a subcutaneous injection and its major 
side effects include injection site reactions and thrombocytopaenia [119]. Emerging evidence 
suggests that low platelet count is associated with an increased risk of severe disease and mortality 
in patients with COVID-19 [120-122]. Whether this is directly causative is unknown; however, 
mechanisms for COVID-19-induced thrombocytopaenia have been suggested [123]. Based on these 
data, it is currently felt that the safest option would be to withhold treatment until the patient 
recovers. 
Recommendation 11:  
Any proposed changes to therapy in patients with FCS should be discussed with a lipid specialist 
familiar with the management of the condition. If a patient with FCS is admitted into hospital, a 
discussion between the acute hospital team, lipid specialist and dietitians should occur at the 
earliest opportunity. For specific treatment strategies, we recommend: 
- Very-low fat diet should be maintained in all patients including those on par-enteral feeding 
(1, C-LD).  
- Oil based medications drugs, like propofol, should be avoided in patients who need assisted  
ventilation and sedation (1, C-LD). 
- For statins, fibrates and other lipid lowering medications, please refer to the 
recommendations above.  
- We recommend Volanesorsen is temporarily withheld in FCS patients with confirmed 
diagnosis of COVID-19 (1, C-EO).  
- Further assessment should be conducted to restart treatment when the patient has 
recovered (1, C-LD). 
- Low platelet count during COVID-19 infection should not be used to permanently 
withhold treatment (C-LD).  
Conclusion 
Many studies show a favourable effect of statin therapy in acutely ill patients and some studies show 
no statistically significant impact on outcome; reassuringly, however, no study to date has 
demonstrated harm. Lipid-lowering therapy has a well-established role in both the primary and 


































































HEART UK Consensus statement: Lipid lowering therapy in COVID 19 
 15 
much needed trial data, it follows that these drugs should be continued wherever possible. 
Importantly, COVID19 is a new disease with a scarce evidence base upon which to make 
recommendations; however, with the rapid evolution of clinical studies, inevitably guidelines may 
need further revision.  
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Class (Strength) of Recommendation 
(COR) 
Description Benefit vs Risk 
Class I - Strong - Is recommended, indicated and useful 
- Should be performed 
- Is indicated, effective and beneficial 
- Comparative-effectiveness phrases** 
 Treatment/strategy A is recommended/indicated in preference 
to B 
 Treatment A should be chosen over treatment B 
Benefit >>> Risk 
Class IIa – Moderate - Is reasonable 
- Can be effective and beneficial 
- Comparative-effectiveness phrases** 
 Treatment/strategy A is probably recommended/indicated in 
preference to B 
 It is reasonable to choose treatment A over treatment B  
Benefit >> Risk 
Class IIb – Weak - May be reasonable but usefulness may be unclear or not well established Benefit  Risk 
Class III – No benefit - Is not recommended 
- Not indicated  
- Should not be performed  
Benefit = Risk 
Class III - Harm - Potentially harmful  
- Should not be performed  
Benefit < Risk 
Table 1B 
Level (Quality) of Evidence (LOE) Description  Supporting evidence 
Level A - High quality evidence*** from > 1 RCT 
- Meta-analysis of high quality RCTs 
-One or more RCTs corroborated by high quality registry 
studies 
RCTs/meta-analysis/registries  
Level B – R - Moderate quality evidence*** from 1 or more RCT 
- Meta-analysis of moderate quality RCTs 
RCTs/meta-analysis 
Level B - NR - Moderate quality evidence*** from 1 or more well 
designed, well executed non-randomised, observational or 
registry studies 
- Meta-analyses of such studies  
Non- randomised clinical trials 
Level C - LD - Randomised or non-randomised, observational or registry 
studies with limitations of design or execution 
- Meta-analyses of such studies 
- Physiological mechanistic studies 
RCT or non-RCT but with limited 
data  
Level A – EO Consensus expert opinion based on clinical experience  Non-Randomised clinical trials 
Table 1A and B:  ACC/AHA guideline recommendation system: Applying class of recommendation and level of evidence to clinical strategies, intervention, treatments, or diagnostic 
testing in patients care.*  Adapted from Halperin et al [10]. 
COR and LOE are determined independently (any COR may be paired with any LOE). 
A recommendation with LOE C does not imply that the recommendation is weak. Many important clinical questions addressed in guidelines do not lend themselves to clinical trials. 
Although RCTs are unavailable, there may be a very clear clinical consensus that a particular test or therapy is useful or effective.  
 
*The outcome or result of the intervention should be specified (an improved clinical outcome or increased diagnostic accuracy or incremental prognostic information) 
 
**For comparative-effectiveness recommendations (COR I and IIa; LOE A and only), studies that support the use of comparator verbs should involve direct comparisons of treatments or 
strategies being evaluated 
 
***The method of assessing quality is evolving, including the application of standardised, widely used, and preferably validated evidence grading tools; and for systematic reviews, the 
incorporation of an Evidence Review Committee  
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Table 2 Statins 
Atorvastatin Simvastatin Rosuvastatina Fluvastatin Pitavastatina Pravastatin 
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a. Pitavastatin is minimally metabolised by the cytochrome P450 enzymes are therefore is not subject to interactions involving enzyme inhibitors and inducers.[125] 
b. There is disquiet regarding the risk of ventricular arrythmias with hydroxychloroquine use in COVID19 patients. A study showing increased risk published in the Lancet was recently 
retracted [139]. 
c. We like to emphasise the risk of myositis with all statins and all macrolide antibiotics. 
NSI- No Significant interactions. 









Remdesivir – part 
metabolised by CYP3A4[127] 
May compete for 
metabolism [127] 
Recommend: 
Switch to low dose 
Rosuvastatin 
May compete for 
metabolism [127] 
Recommend: 
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Tocilizumab[136] – Impacts 
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Fibrates are contraindicated as GFR declines. To reassess if there is a decline in renal function and consider stopping (please refer to recommendation 4). 
Fibrates can interact with anticoagulants. This should be taken in consideration if oral anticoagulants used. 
Refer to individual drugs SmPC and the University of Liverpool’s Drug interaction site (www.covid19-druginteractions.org). 
 NSI- No Significant interactions. 
 
Table 3 Fibrates 
Fenofibrate  Bezafibrate Gemfibrozil Clofibrate 
























Lopinavir NSI- Recommend: 
Continue [141, 142]  
Not studied directly 
but likely Safe- 
Recommend: 
Continue with 
monitoring [141, 142]  
NSI - recommend to 
continue however 
efficacy of 









Ritonovir  NSI- Recommend: 
Continue [141, 142, 
144]  
Not studied directly 
but likely Safe- 
Recommend: 
Continue with 
monitoring [141, 142]  
NSI - recommend to 
continue however 
efficacy of 









Ribavirin Not studied directly 






Not studied directly 




Not studied directly 




Inteferon-Beta 1 -Alpha Increased risk of 
Hepatoxicity – 
Recommend: Stop  
Increased risk of 
Hepatoxicity – 
Recommend:  stop 
Increased risk of 
Hepatoxicity – 
Recommend:  stop 
Increased risk of 
Hepatoxicity - 
Recommend:  stop 
Melatonin 
 
Not directly studied 
but likely safe- 
Recommend: 
Continue with LFT 
monitoring 
Not directly studied 
but likely safe- 
Recommend: 
Continue with LFT 
monitoring 
Not directly studied 
but likely safe- 
Recommend: 
Continue with LFT 
monitoring 
Not directly studied 
but likely safe- 
Recommend: 





Not directly studied 
but likely safe- 
Recommend: 
Continue 












Azithromycin [146] Not directly studied 
but likely safe- 
Recommend: 
Continue with LFT 
monitoring 
Not directly studied 
but likely safe- 
Recommend: 
Continue with LFT 
monitoring 
Not directly studied 
but likely safe- 
Recommend: 
Continue with LFT 
monitoring 
Not directly studied 
but likely safe- 
Recommend: 
Continue with LFT 
monitoring 
















Ivermectin Not directly studied 
but likely safe- 
Recommend: 
Continue with LFT 
monitoring 
Not directly studied 
but likely safe- 
Recommend: 
Continue with LFT 
monitoring 
Not directly studied 
but likely safe- 
Recommend: 
Continue with LFT 
monitoring 
Not directly studied 
but likely safe- 
Recommend: 
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We recommend stopping niacin in acutely ill patients with COVID-19  
For other drugs potential interactions please visit https://www.hiv-druginteractions.org/ also BNF, Stockley’s Drug Interactions, individual drugs SmPC and consult with your pharmacy department.  
NSI- No Significant interactions. 
 
Table 4 
Ezetimibe [147, 148] PCSK9 inhibitors [75] Omega-3- fatty acids Lomitapide  [116] 
Remdesivir Not directly studied but likely safe-Recommend: Continue Not directly studied but likely safe-Recommend: Continue Not directly studied but likely safe-
Recommend: Continue 
Not directly studied. Recommend: to withhold treatment 
temporarily. 
Hydroxychloroquine Not directly studied but likely safe-Recommend: Continue Not directly studied but likely safe-Recommend: Continue NSI –Recommend: Continue [149] Not directly studied.  Recommend: to withhold treatment 
temporarily. 
 
Lopinavir Not directly studied but likely safe-Recommend: Continue Not directly studied but likely safe-Recommend: Continue NSI –Recommend: Continue [150] Lopinavir is predicted to markedly increase the exposure to 
lomitapide and risk of hepatotoxicity.  Recommend: to 
withhold treatment temporarily. 
 
Ritonavir  Not directly studied but likely safe-Recommend: Continue Not directly studied but likely safe-Recommend: Continue NSI –Recommend: Continue [150] Ritonavir is predicted to markedly increase the exposure to 
lomitapide and risk of hepatotoxicity.  Recommend: to 
withhold treatment temporarily. 
 
Ribavirin Not directly studied but likely safe-Recommend: Continue Not directly studied but likely safe-Recommend: Continue NSI – Recommend: Continue [151-153] Not directly studied.  Recommend: to withhold treatment 
temporaril 
Interferon-Beta 1 -Alpha Not directly studied but likely safe-Recommend: Continue Not directly studied but likely safe-Recommend: Continue NSI – Recommend: Continue [154, 
155] 








Not directly studied but likely safe-Recommend: Continue Not directly studied but likely safe-Recommend: Continue Not directly studied but likely safe –
Recommend: Continue 





Not directly studied but likely safe-Recommend: Continue  Not directly studied but likely safe-Recommend: Continue NSI –   Recommend: Continue  Not directly studied.  Recommend: to withhold treatment 
temporarily. 
 
Azithromycin Not directly studied but likely safe-Recommend: Continue Not directly studied but likely safe-Recommend: Continue NSI –   Recommend: Continue [156] Azithromycin is a weak CYP3A4 inhibitor and is predicted to 
increase exposure to lomitapide. Recommend:  to withhold 
treatment temporarily. 
Tocilizumab Not directly studied but likely safe-Recommend: Continue Not directly studied but likely safe-Recommend: Continue Not directly studied but likely safe-
Recommend: Continue 
Not directly studied -Recommend: to withhold treatment 
temporarily. 
Ivermectin Not directly studied but likely safe-Recommend: Continue Not directly studied but likely safe-Recommend: Continue Not directly studied but likely safe-
Recommend: Continue 
Not directly studies. Some references suggest that 
lomitapide may slightly increase levels of ivermectin. 
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The paper was revised accordingly, is clear, well written using the available evidence at its best and 
certainly will guide physicians in dealing with dyslipidemic patients with COVID-19. My only 
suggestion is that please add an extra table explaining the recommendation grading used in it since 
many physicians may not be aware of the adopted criteria proposed by the ACC/AHA. 
 
Many thanks for the comments. We have now added table 1a and 1b as per the editor’s request. 
These tables have been incorporated into the main body of the manuscript however we are equally 
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